scispace - formally typeset
E

Eduardo Anitua

Researcher at University of the Basque Country

Publications -  346
Citations -  16253

Eduardo Anitua is an academic researcher from University of the Basque Country. The author has contributed to research in topics: Implant & Medicine. The author has an hindex of 54, co-authored 295 publications receiving 14093 citations. Previous affiliations of Eduardo Anitua include Leonardo & University of Milan.

Papers
More filters
Journal ArticleDOI

Autologous platelets as a source of proteins for healing and tissue regeneration

TL;DR: The aim is to discuss the ways in which platelets may provide such unexpected beneficial therapeutic effects in clinical situations requiring rapid healing and tissue regeneration.
Journal Article

Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants.

TL;DR: Preliminary clinical evidence is presented of the beneficial effect of the use of plasma rich in growth factors of autologous origin, which can introduce several advantages, including the enhancement and acceleration of bone regeneration and more rapid and predictable soft tissue healing.
Journal ArticleDOI

Comparison of Surgically Repaired Achilles Tendon Tears Using Platelet-Rich Fibrin Matrices

TL;DR: The operative management of tendons combined with the application of autologous PRGF may present new possibilities for enhanced healing and functional recovery in patients affected by musculoskeletal traumatic injuries.
Journal ArticleDOI

Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture.

TL;DR: It is suggested that administering autologous platelet‐rich clots may be beneficial to the treatment of tendon injuries by inducing cell proliferation and promoting the synthesis of angiogenic factors during the healing process.
Journal ArticleDOI

New insights into and novel applications for platelet-rich fibrin therapies

TL;DR: The therapeutic use of autologous platelet-rich plasma is highlighted and some of the obstacles and challenges that need to be addressed to maintain progress in this field are discussed.